Preimplantation Genetic Testing (PGT) Market Size

Preimplantation Genetic Testing (PGT) Market Size

The global preimplantation genetic testing market was valued at USD 780.8 million in 2023 and is estimated to grow at a CAGR of 9.4% from 2024 to 2032. The market growth is primarily driven by increasing prevalence of genetic disorders in newborns and rising awareness of reproductive health. PGT provides a proactive approach to identifying genetic abnormalities in embryos before implantation, addressing the concerns of families seeking to prevent hereditary diseases.

To get key market trends

  Download Free Sample

Also, growing advancements in reproductive technologies, particularly in vitro fertilization (IVF), have improved the accessibility of PGT. The rising maternal age and declining fertility rates further support the market's growth, as couples increasingly consider genetic testing to ensure healthy pregnancies. For instance, the Society at a Glance 2024 edition reported a concerning decline in fertility rates, particularly in countries such as Italy, Spain, and Korea. These countries are experiencing exceptionally low fertility rates, resulting in increasing pressure on couples to maximize their chances of successful pregnancies.

This trend is expected to boost the demand for PGT services as more couples seek to ensure genetic health, thereby driving market growth. Additionally, societal acceptance of assisted reproductive technology (ART) and genetic testing is poised to project significant expansion in the coming years.

PGT is a reproductive technology used during IVF to screen embryos for genetic abnormalities before implantation. This process involves extracting a few cells from an embryo and analyzing them for specific genetic conditions or chromosomal disorders.